<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02205554</url>
  </required_header>
  <id_info>
    <org_study_id>Syntrix-Omni-Pain-101</org_study_id>
    <secondary_id>R44DA027304</secondary_id>
    <nct_id>NCT02205554</nct_id>
  </id_info>
  <brief_title>Omnitram Pharmacokinetic Study In Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Triple Cross-Over Study Investigating The Safety, Oral Steady-State Pharmacokinetics, And Clinical Activity Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syntrix Biosystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Syntrix Biosystems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety, pharmacokinetic properties (the&#xD;
      absorption, distribution and excretion), and analgesic activity of Omnitram (10 mg tablets),&#xD;
      Tramadol (Ultram, 50 mg tablet) following oral administration of 9 doses healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, single-center, randomized, double-blind, placebo-controlled, three-period&#xD;
      cross-over study to compare the safety, steady-state oral pharmacokinetics, and clinical&#xD;
      activity of overencapsulated: 20 mg Omnitram (2x10 mg tablets), 50 mg Tramadol (1x50 mg&#xD;
      Ultram tablet), and placebo.&#xD;
&#xD;
      Forty male subjects in normal health, 21 to 55 years of age, will be randomized to three&#xD;
      parallel arms (N=~13 each) to ingest a total of 9 doses of Omnitram, Tramadol, or placebo in&#xD;
      a first treatment segment (one dose every 6 hours). Around the 9th dose blood samples are&#xD;
      collected to quantify plasma Tramadol and Metabolite 1 (M1) enantiomers. After the 9th dose,&#xD;
      pain tolerance is assessed with a cold pressor test (ice cold water immersion). After the 7th&#xD;
      dose abuse liability measures and pupil diameter will be assessed. Subjects will washout for&#xD;
      7 days after the first treatment segment and second treatment segment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Omnitram and Tramadol Steady State Maximum and Minimum Concentrations</measure>
    <time_frame>0.0, 1.0, 1.5, 2.0, 2.5, and 4.0 hours after the 9th dose of Omnitram and Tramadol.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cold Water Induced-Pain Reported On a 0 to 10 Scale</measure>
    <time_frame>On Study Day 2, Study Day 12, and Study Day 22, after the 9th dose of Omnitram, Tramadol, and placebo.</time_frame>
    <description>Subject immerses a hand in cold water for a maximum of 3 minutes and reports level of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abuse Liability Assessed With Visual Analogue Scales</measure>
    <time_frame>On Study Day 1, Study Day 11, and Study Day 21, after the 7th dose of Omnitram, Tramadol, and placebo.</time_frame>
    <description>Subjects read a question and respond by placing a mark on a visual analogue scale.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pupil Size</measure>
    <time_frame>On Study Day 1, Study Day 11, and Study Day 21, after the 7th dose of Omnitram, Tramadol, and placebo.</time_frame>
    <description>A pupilometer is used to measure eye pupil size.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Omnitram-Tramadol-Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol-Placebo-Omnitram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tramadol 20 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Omnitram-Tramadol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omnitram</intervention_name>
    <description>Nine 20 mg doses administered every 6 hours</description>
    <arm_group_label>Omnitram-Tramadol-Placebo</arm_group_label>
    <arm_group_label>Placebo-Omnitram-Tramadol</arm_group_label>
    <arm_group_label>Tramadol-Placebo-Omnitram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>Nine 50 mg doses administered every 6 hours.</description>
    <arm_group_label>Omnitram-Tramadol-Placebo</arm_group_label>
    <arm_group_label>Placebo-Omnitram-Tramadol</arm_group_label>
    <arm_group_label>Tramadol-Placebo-Omnitram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nine doses administered every 6 hours.</description>
    <arm_group_label>Omnitram-Tramadol-Placebo</arm_group_label>
    <arm_group_label>Placebo-Omnitram-Tramadol</arm_group_label>
    <arm_group_label>Tramadol-Placebo-Omnitram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male with normal vital signs: systolic blood pressure &gt; 90 mm Hg and &lt; 140 mm&#xD;
             Hg; diastolic blood pressure &gt; 50 mm Hg and &lt; 90 mm Hg; pulse 50 to 100 beats per&#xD;
             minute; respiratory rate 12 to 20 breathes per minute&#xD;
&#xD;
          2. Between the ages of 21 and 55 years of age&#xD;
&#xD;
          3. Able and willing to give informed consent&#xD;
&#xD;
          4. Able to comply with all study procedures&#xD;
&#xD;
          5. Have adequate hematologic function as evidenced by the following screening results:&#xD;
&#xD;
               -  White Blood Cell (WBC) &gt;3,500/mm3 and &lt; 12,000/mm3;&#xD;
&#xD;
               -  Platelet Count &gt; 150,000/mm3 and &lt; 540,000/mm3;&#xD;
&#xD;
               -  Hemoglobin &gt; 12.5 gm/dL and &lt; 20.5 gm/dL.&#xD;
&#xD;
             Have adequate liver function as evidenced by the following screening results:&#xD;
&#xD;
               -  Aspartate transaminase (AST) ≤ 60 IU/L;&#xD;
&#xD;
               -  Alanine transaminase (ALT) ≤ 83 IU;&#xD;
&#xD;
               -  Alkaline Phosphatase ≤ 150 IU/L;&#xD;
&#xD;
               -  Total Bilirubin ≤ 1.2 mg/dL;&#xD;
&#xD;
               -  Prothrombin Time (PT) &lt; 1.2 upper limit of normal (ULN); Partial Thromboplastin&#xD;
                  Time (PTT) &lt; 1.2 ULN.&#xD;
&#xD;
          6. Electrocardiogram (ECG) within normal limits as determined by the PI&#xD;
&#xD;
          7. Have adequate renal function as evidenced by the following screening result:&#xD;
&#xD;
             Glomerular filtration rate (GFR) calculated by Cockcroft-Gault formula &gt;60 ml/min.&#xD;
&#xD;
             Urinalysis demonstrating &lt; +1 glucose, +1 ketones, and +1 protein&#xD;
&#xD;
          8. Negative urine test for substances of abuse, including opiates, per clinical research&#xD;
             unit (CRU) standards&#xD;
&#xD;
          9. Negative serology tests for HIV, hepatitis B surface antigen and hepatitis C virus&#xD;
             antibody&#xD;
&#xD;
         10. Body Mass Index (BMI) 19.0 to 32 kg/m&#xD;
&#xD;
         11. Cold pressor screening results as follows: 1) pain tolerance of &gt; 20 seconds and &lt;120&#xD;
             seconds&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Oral temperature &gt; 38°C or history of current illness&#xD;
&#xD;
          2. History of seizures, epilepsy, or recognized increase risk of seizure (e.g., head&#xD;
             trauma, metabolic disorders, alcohol or drug withdrawal)&#xD;
&#xD;
          3. History of cirrhosis or laboratory evidence of liver disease&#xD;
&#xD;
          4. Use of alcohol within 24 hours of day -1 until the end of the study; and grapefruit,&#xD;
             grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), or grapefruit juice&#xD;
             or grapefruit-related juices, or other medication, within 7 days of study drug&#xD;
             administration and until the end of the study&#xD;
&#xD;
          5. History of previous anaphylaxis, severe allergic reaction to Tramadol, codeine, or&#xD;
             other opioid drugs&#xD;
&#xD;
          6. Use of monoamine oxidase (MAO) inhibitors (including linezolid), Serotonin Reuptake&#xD;
             Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and prescription or over-the&#xD;
             counter (OTC) medications known to induce or inhibit drug metabolism, including&#xD;
             cytochrome P450 2D6 (CYP2D6), and other drugs that may affect the serotonergic&#xD;
             neurotransmitter systems including, but not limited to, triptans, dextromethorphan,&#xD;
             tricyclic antidepressants, bupropion, lithium, tramadol, dietary supplements such as&#xD;
             tryptophan and St. John's Wort, and antipsychotics or other dopamine antagonists.&#xD;
             These restrictions are to be maintained from 14 days before study day -1, until the&#xD;
             subject completes the study&#xD;
&#xD;
          7. Any other unstable acute or chronic disease that could interfere with the evaluation&#xD;
             of the safety of the study drug as determined by the principal Investigator in&#xD;
             dialogue with the Sponsor Medical Monitor&#xD;
&#xD;
          8. Unlikely to comply with the study protocol&#xD;
&#xD;
          9. Known or suspected alcohol or drug abuse within the past 6 months&#xD;
&#xD;
         10. Received another investigational agent within 4 weeks of Day 0, or within five&#xD;
             half-lives of Day 0, whichever is longer; or receiving any other investigational agent&#xD;
             during this study&#xD;
&#xD;
         11. Any concurrent disease or condition that in the opinion of the investigator impairs&#xD;
             the subject's ability to complete the trial. Psychological, familial, sociological,&#xD;
             geographical or medical conditions which, in the Investigator's opinion, could&#xD;
             compromise compliance with the objectives and procedures of this protocol, or obscure&#xD;
             interpretation of the trial data&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shawn Searle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA/CRI Lifetree Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stuart Kahn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Syntrix Biosystems, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRI Lifetree Research Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>July 28, 2014</study_first_submitted>
  <study_first_submitted_qc>July 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2014</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Analgesia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

